
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is expected to have a positive outlook as their RAPID pathway aims to expedite the approval process for their lead product candidate, Revita. With funds to sustain operations until early 2027 and strong results expected in the fourth quarter of 2026, recent studies have shown Revita's potential to effectively maintain weight loss. Despite facing standard risks in the industry, Fractyl Health's data supports the potential success of Revita as a one-time treatment option for weight control.
Bears say
Fractyl Health is facing significant challenges in its goal of treating obesity and type 2 diabetes, as its lead product candidate Revita has not shown strong enough weight loss results and has minimal effect on HbA1c levels. This could limit the company's potential for adoption and commercial success, especially considering the small sample size and relatively short follow-up period in clinical trials. Additionally, the company's potential De Novo reclassification in 2026 and pivotal cohort data in 4Q26 may not be enough to offset these challenges and justify a positive outlook on the stock.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares